// App-Quantinova.ai

PB1711 : PACIFICA: A RANDOMIZED, CONTROLLED PHASE 3 STUDY OF PACRITINIB VERSUS PHYSICIAN'S CHOICE IN PATIENTS WITH PRIMARY OR SECONDARY MYELOFIBROSIS AND SEVERE THROMBOCYTOPENIA

Researchers

Presenter

  • John Mascarenhas

Principal Investigators

  • Aaron Gerds

  • Jean-Jacques Kiladjian

  • Konstanze Dhner

  • Sarah Buckley

  • Jennifer Smith

  • Adam Craig

  • Simran Singh

  • Srdan Verstovsek

  • Claire Harrison

Medical Centers

  • CTI BioPharma Corp.,Seattle,United States

  • Aphp Saint-Louis Hospital, Paris, France

  • Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

  • University of Ulm, Ulm, Germany

  • Guy's And St Thomas NHS Foundation Trust, London, United Kingdom

  • CTI BioPharma Corp.,Seattle,United States

  • Icahn School of Medicine at Mount Sinai, New York, New York, United States

  • University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Locations

  • United States

  • France

  • Germany

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Blood/haematological Diseases

Disease

  • Thrombocytopenia

  • Myelofibrosis

Biomarkers

  • Sustained virological response

Drug/Treatment

  • Hydroxyurea

  • Ruxolitinib phosphate

  • Pacritinib

  • Danazol

Outcome

  • N/A

Study Design

  • Randomized

  • Multinational

  • Multicenteric

  • Controlled

Phase

  • III

Study Id's

  • NCT03165734

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved